Refractory immune thrombocytopenia: Lessons from immune dysregulation disorders.
作者信息
Costagliola Giorgio, Consolini Rita
机构信息
Section of Clinical and Laboratory Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
出版信息
Front Med (Lausanne). 2022 Sep 20;9:986260. doi: 10.3389/fmed.2022.986260. eCollection 2022.
Abstract
摘要
相似文献
1
Refractory immune thrombocytopenia: Lessons from immune dysregulation disorders.难治性免疫性血小板减少症：免疫失调性疾病的经验教训。
Front Med (Lausanne). 2022 Sep 20;9:986260. doi: 10.3389/fmed.2022.986260. eCollection 2022.
2
Immune cytopenias as a continuum in inborn errors of immunity: An in-depth clinical and immunological exploration.免疫细胞减少症作为固有免疫缺陷中的一个连续谱：深入的临床和免疫学研究。
Immun Inflamm Dis. 2021 Jun;9(2):583-594. doi: 10.1002/iid3.420. Epub 2021 Apr 10.
3
Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study.自身免疫性血细胞减少症和免疫表型失调作为先天性免疫缺陷的预警信号：一项前瞻性研究的结果。
Front Immunol. 2022 Jan 4;12:790455. doi: 10.3389/fimmu.2021.790455. eCollection 2021.
4
Precision Medicine in the Treatment of Primary Immune Deficiency Patients With Disorders of Immune Dysregulation.精准医学在免疫调节紊乱相关原发性免疫缺陷病患者治疗中的应用
Clin Rev Allergy Immunol. 2022 Aug;63(1):1-8. doi: 10.1007/s12016-021-08871-4. Epub 2021 Jun 24.
5
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain.在西班牙，用依洛尤单抗和利妥昔单抗治疗原发免疫性血小板减少症的成本-应答分析。
Farm Hosp. 2020 Oct 15;44(6):279-287. doi: 10.7399/fh.11525.
6
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.艾曲泊帕乙醇胺用于治疗一名非小细胞肺癌患者中由帕博利珠单抗诱导的难治性免疫相关性血小板减少症。
Lung Cancer. 2020 Aug;146:362-365. doi: 10.1016/j.lungcan.2020.05.015. Epub 2020 May 30.
7
First Report of Severe Autoimmune Hemolytic Anemia During Eltrombopag Therapy in Waldenström Macroglobulinemia-Associated Thrombocytopenia.沃登斯特伦巨球蛋白血症相关性血小板减少症患者接受艾曲泊帕治疗期间发生严重自身免疫性溶血性贫血的首例报告
Onco Targets Ther. 2021 Oct 9;14:5027-5033. doi: 10.2147/OTT.S333189. eCollection 2021.
8
Underlying Inborn Errors of Immunity in Patients With Evans Syndrome and Multilineage Cytopenias: A Single-Centre Analysis.患有 Evans 综合征和多系血细胞减少症患者的潜在先天性免疫缺陷：单中心分析。
Front Immunol. 2022 May 17;13:869033. doi: 10.3389/fimmu.2022.869033. eCollection 2022.
9
Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation.儿童 Evans 综合征伴潜在系统性免疫失调所致难治性自身免疫性血细胞减少症。
Eur J Haematol. 2021 Jun;106(6):783-787. doi: 10.1111/ejh.13600. Epub 2021 Mar 16.
10
Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets.先天性免疫缺陷导致自身免疫性血细胞减少症的发病机制及新的治疗靶点。
Front Immunol. 2022 Apr 6;13:846660. doi: 10.3389/fimmu.2022.846660. eCollection 2022.
引用本文的文献
1
Evaluating the prevalence of inborn errors of immunity in adults with chronic immune thrombocytopenia or Evans syndrome.评估成人慢性免疫性血小板减少症或 Evans 综合征中先天性免疫缺陷的患病率。
Blood Adv. 2023 Dec 12;7(23):7202-7208. doi: 10.1182/bloodadvances.2023011042.
2
Pathogenesis of refractory ITP: Overview.难治性 ITP 的发病机制：概述。
Br J Haematol. 2023 Oct;203(1):10-16. doi: 10.1111/bjh.19083.
本文引用的文献
1
ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.ALPS、FAS 及其他：从先天性免疫缺陷到获得性免疫缺陷。
Ann Hematol. 2022 Mar;101(3):469-484. doi: 10.1007/s00277-022-04761-7. Epub 2022 Jan 20.
2
Chronic Refractory Immune Thrombocytopenia Is Associated With Variants in Immune Genes.慢性难治性免疫性血小板减少症与免疫基因变异有关。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211059813. doi: 10.1177/10760296211059813.
3
Autoimmunity in Primary Immunodeficiency Disorders: An Updated Review on Pathogenic and Clinical Implications.原发性免疫缺陷病中的自身免疫：关于发病机制和临床意义的最新综述
J Clin Med. 2021 Oct 15;10(20):4729. doi: 10.3390/jcm10204729.
4
Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.JAK 抑制剂在治疗先天性免疫缺陷中的新地位。
Front Immunol. 2021 Sep 17;12:717388. doi: 10.3389/fimmu.2021.717388. eCollection 2021.
5
Therapeutic options for CTLA-4 insufficiency.CTLA-4 不足的治疗选择。
J Allergy Clin Immunol. 2022 Feb;149(2):736-746. doi: 10.1016/j.jaci.2021.04.039. Epub 2021 Jun 7.
6
Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.免疫缺陷与自身炎症之间的十字路口处的淋巴结病：一个有趣的挑战。
Clin Exp Immunol. 2021 Sep;205(3):288-305. doi: 10.1111/cei.13620. Epub 2021 Jun 20.
7
Clinical, immunological, and genetic features in 780 patients with autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like diseases: A systematic review.自身免疫性淋巴组织增生综合征（ALPS）及 ALPS 样疾病 780 例患者的临床、免疫及遗传学特征：系统评价。
Pediatr Allergy Immunol. 2021 Oct;32(7):1519-1532. doi: 10.1111/pai.13535. Epub 2021 May 27.
8
Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.222 例 CTLA-4 部分功能缺失与 212 例 LRBA 缺陷患者的综合比较：一项系统评价。
Clin Exp Immunol. 2021 Jul;205(1):28-43. doi: 10.1111/cei.13600. Epub 2021 May 3.
9
Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review.STAT1 种系获得性功能和失能性功能突变的临床意义：系统综述。
Front Immunol. 2021 Mar 11;12:654406. doi: 10.3389/fimmu.2021.654406. eCollection 2021.
10
Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update.慢性免疫性血小板减少症发病机制的新见解：从基础到临床的更新。
Blood Rev. 2021 Sep;49:100827. doi: 10.1016/j.blre.2021.100827. Epub 2021 Mar 18.
Zotero 插件